Mitragynine Pseudoindoxyl Synthesis and Regulatory Crackdown
Summary
Mitragynine pseudoindoxyl is a potent semi-synthetic derivative and metabolite of the primary kratom alkaloid mitragynine. Discovered in the late 1960s by researchers at Smith Kline & French through fungal biotransformation, it remained largely obscure for decades despite exhibiting significantly higher mu-opioid receptor potency than morphine. Modern chemical isolation and solvent-free neat thermal isomerization enabled companies like Shaman Pharmaceuticals to produce the substance at commercial scale, leading to retail sales in gas stations, commercial testing in conflict zones such as Ukraine, and rising scrutiny following media panics and fatal overdose reports linked to unregulated kratom extracts. Law enforcement raids across the United States and abroad reflect the shifting legal environment, culminating in emergency scheduling proposals by drug enforcement agencies to place mitragynine pseudoindoxyl into Schedule I.